Company / Free Cash Flow
Solid Biosciences Inc. Free Cash Flow History
FY2018-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$57.5M
FY2022
5-year range
-$97.1M / -$20.5M
FY2018-FY2022
Trend
+40.8%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow returned to growth in FY2022 after 3 years of decline, reaching -$57M.
Based on SEC 10-K filings.
-$57M in FY2022.
Improved from -$78M to -$57M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, free cash flow increased 40.8% year-over-year.
- Peak free cash flow was recorded in FY2018.
- Lowest free cash flow in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 1.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | -$57.5M | +40.8% |
| FY2021 | -$97.1M | -24.5% |
| FY2020 | -$78.0M | -71.4% |
| FY2019 | -$45.5M | -121.8% |
| FY2018 | -$20.5M | - |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026